Bromide

Bromide

SCHEMBL3786484

Br.Br.CCN[C@@H]1Cc2cc3nc(N)sc3cc2C1

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR1A known ✓ P08908 1/20 0.40
DRD2 P14416 16/20 0.97
DRD3 P35462 2/20 0.59
DRD4 P21917 1/20 0.59
KCNH2 Q12809 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
TSHR P16473 2/20 0.44
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HTR7 P34969 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8006961 0.99 DRD2 (1.00) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL8006320 0.99 DRD2 (1.00) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL13729374 0.99 DRD2 (1.00) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL13730744 0.88 DRD2 (1.00) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL13729821 0.82 DRD2 (0.72) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL3780137 0.80 DRD2 (0.68) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL3785046 0.77 DRD2 (0.64) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL8008834 0.76 DRD2 (0.80) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL7996935 0.76 DRD2 (0.61) DRD2DRD3DRD4KCNH2SMN1; SMN2
SCHEMBL7393183 0.76 DRD2 (0.61) DRD2DRD3DRD4KCNH2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254876-A1 COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS AstraZeneca AB (SE) 2010-12-01 EP disclosed
WO-2009105026-A1 COMPOUND (R) -N*6*-ETHYL-6, 7-DIHYDRO-5H-INDENO (5, 6- D) THIAZOLE-2, 6-DIAMINE AND THE USE AS ANTIPSYCHOTICS ASTRAZENECA AB (SE) 2009-08-27 WO disclosed
US-20090215841-A1 D2 Receptor Ligand-078 ASTRAZENECA AB (SE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215841-A1 D2 Receptor Ligand-078 TACR2, TACR1, GPR174 HTR1A 87/4885DRD2 39/4885DRD3 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.